CX Institutional
CORT icon

CX Institutional’s Corcept Therapeutics CORT Stock Holding History

CX Institutional’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$38K Buy
326
+1
+0.3% +$108 ﹤0.01% 1076
2026
Q2 		$28K Buy
325
+2
+0.6% +$121 ﹤0.01% 1090
2026
Q1 		$13K Buy
+323
New +$12.1K ﹤0.01% 1218

Other funds holding CORT

KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Stanley-Laman Group
Stanley-Laman Group Berwyn, Pennsylvania $915M AUM 50.26% 1-Year Est. Return
Amalgamated Bank
Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Linden Thomas Advisory Services
Linden Thomas Advisory Services Charlotte, North Carolina $1.26B AUM 37.95% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

CX Institutional's CORT Position: Q3 2026 in Review

CX Institutional increased its Corcept Therapeutics (CORT) stake by 0.31% in Q3 2026, buying an estimated $108 and bringing the position to 326 shares worth $38K. The position accounts for ﹤0.01% of the portfolio, ranked #1076.

CX Institutional first reported a position in CORT in Q1 2026 and has held it in 3 quarters since. 90 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • CX Institutional held 326 shares of Corcept Therapeutics worth $38K as of Q3 2026.
  • CX Institutional bought 1 Corcept Therapeutics share in Q3 2026, an estimated $108.
  • Corcept Therapeutics made up ﹤0.01% of CX Institutional's portfolio in Q3 2026, its #1076 holding.
  • CX Institutional first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 90 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.